Skip to main
FHTX

Foghorn Therapeutics (FHTX) Stock Forecast & Price Target

Foghorn Therapeutics (FHTX) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Foghorn Therapeutics Inc. showcases a promising outlook for its flagship program, FHD-909, which exhibits enhanced SMARCA2 coverage and blockade, suggesting improved patient responses and treatment durability. The potential for the stock to increase by 40-50% in the base case scenario, driven by an overall response rate (ORR) of 10-20% and a duration of response (DoR) ranging from 4-6 months, positions it favorably within the clinical landscape. Additionally, the significant synergy observed when combining FHD-909 with other therapies indicates robust potential for treatment efficacy, particularly in second-line non-small cell lung cancer (NSCLC) settings, further supporting a positive long-term view on the company's financial performance.

Bears say

Foghorn Therapeutics Inc faces significant challenges, as its clinical data has reportedly not met the internal threshold for clinical benefit, potentially affecting its flagship program, FHD-909, and resulting in a necessary pivot due to balance sheet constraints. Additionally, preclinical studies indicate that the candidate molecule exhibits slower degradation kinetics and a hook effect, further raising concerns about its clinical efficacy in treating SMARCA4 mutant NSCLC. The negative outlook is compounded by projections suggesting a downside of 30-40% in stock value amid low response rates and significant treatment-related adverse events, which would yield an unfavorably undifferentiated profile compared to existing therapies.

Foghorn Therapeutics (FHTX) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Foghorn Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Foghorn Therapeutics (FHTX) Forecast

Analysts have given Foghorn Therapeutics (FHTX) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Foghorn Therapeutics (FHTX) has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Foghorn Therapeutics (FHTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.